Nitroglycerin topical - Covis Pharma/MediQuest

Drug Profile

Nitroglycerin topical - Covis Pharma/MediQuest

Alternative Names: MQX-503; Vascana

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediQuest Therapeutics
  • Developer Covis Pharma; MediQuest Therapeutics
  • Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Raynaud's disease

Most Recent Events

  • 26 Sep 2017 Discontinued - Phase-III for Raynaud's disease in Canada (Topical,gel)
  • 26 Sep 2017 Discontinued - Phase-III for Raynaud's disease in European Union (Topical,gel)
  • 26 Sep 2017 No recent reports on development identified - Phase-III for Raynaud's disease in USA (Topical,cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top